Ensol Biosciences, Inc.
KKRX:1406107,830.00
KRW
-760.00
(-8.85%)
ISIN
KR7140610007
Return %
Stock
S&P 500
1Y
-47.09
14.39
3Y
-15.08
81.42
5Y
-50.60
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Hae-Jin Kim
- Full Time Employees
- 28
- Sector
- Distribution services
- Industry
- Medical distributors
- Address
- Daejeon South Korea
- IPO Date
- Sep 10, 2018
- Website
- ensolbio.co.kr
- Similar Companies
- Business
- Ensol Biosciences, Inc. is a South Korea-based biopharmaceutical company that specializes in the discovery and development of peptide-based therapeutics and innovative biopharmaceuticals for degenerative, oncological, central nervous system, and metabolic diseases. Founded in 2001 and headquartered in Daejeon, South Korea, the company operates primarily through the application of proprietary artificial intelligence and bio-big data platforms to engineer first-in-class and best-in-class drug candidates. The company's core products, platforms, and clinical candidates comprise: Knowledge-based In Silico Drug Discovery (KISDD), a proprietary bioinformatics and computational drug discovery platform for screening and optimizing peptide candidates; Ensol Trans-Omics Network System (ETONS), a biological network analysis and text-mining software platform used to elucidate drug mechanisms of action, identify therapeutic targets, and evaluate safety profiles; P2K (Peniel2000 / SB-01), an intradiscal peptide injection developed for the treatment of degenerative disc disease and associated spinal disorders; E1K (Engedi1000), a disease-modifying peptide candidate undergoing clinical development for knee osteoarthritis; C1K (Charis1000), an oncology candidate targeting triple-negative breast cancer; C2K, a pipeline candidate for non-small cell lung cancer; D1K, a Trop-2-targeting peptide-drug conjugate candidate; M1K (Moriah1000), a therapeutic candidate under investigation for Alzheimer's disease; H1K, a metabolic pipeline candidate for obesity; A1K, a therapeutic candidate for atopic dermatitis; and JointVex (EAD100), an approved veterinary intra-articular peptide injection for the treatment of canine osteoarthritis. In recent corporate developments, Ensol Biosciences expanded its global licensing partnership in July 2024 with U.S.-based Spine Biopharma through an agreement valued at up to USD 155 million, expanding the development scope of its lead asset P2K across additional indications including osteoarthritis, fibrotic diseases, and oncology following the completion of U.S. Phase 3 clinical evaluation for degenerative disc disease. Domestically, the company progressed the Phase 3 clinical program for its knee osteoarthritis therapy E1K and entered into an exclusive distribution and commercial licensing agreement with Leaders Cosmetics. Furthermore, following improvements to its balance sheet and transition to positive net equity, Ensol Biosciences initiated steps for a transfer listing from the KONEX board to the KOSDAQ market, engaging Shinhan Securities as the lead underwriter for the listing process.